Deciphex Accepted into MHRA GLP Monitoring Programme and Imminent Attainment of GLP Certification at Exeter Site
Exeter, 24th August 2023 – Deciphex, a pioneering leader in digital pathology solutions, is pleased to announce the acceptance of, Diagnexia UK Limited, into the Medicines and Healthcare products Regulatory Agency (MHRA) GLP Monitoring Programme as a prospective member, and the expected achievement of Good Laboratory Practice (GLP) compliance statement for its cutting-edge facility located in Exeter. This significant milestone emphasizes Deciphex’s dedication to maintaining the highest standards of quality, precision, and regulatory compliance in its operations and enables GLP compliant scanning of Whole Slide Images (WSI) and delivery via the Patholytix platform.
Deciphex can now take your preclinical study glass slides and process them into digital Whole Slide Images (WSI). We can upload them directly and quickly back to your study group maintaining GLP compliance at every step of the process.
The Exeter site’s, Diagnexia UK Limited, acceptance onto the GLP monitoring programme is a testament to Deciphex’s unwavering pursuit of excellence and commitment to providing accurate and dependable data, which is essential for the development and evaluation of pharmaceuticals, medical devices, and other health-related products. Through rigorous adherence to GLP guidelines, Deciphex enhances its capabilities to support clients in their research and development efforts, contributing to the advancement of the Drug Development LifeCycle for our clients.
“We are delighted to have been accepted as a prospective member of the MHRA GLP Monitoring Programme. The successful implementation inspection at our Exeter site by the MHRA gives us confidence in meeting the standards of our Pharma and CRO clients,” stated Shane Ryan, General Manager of Research Pathology at Deciphex.
“This accomplishment highlights our unwavering commitment to maintaining top-quality operations, precision, and regulatory compliance. Our dedication to providing reliable data remains central to our mission of accelerating certainty in the Drug Development LifeCycle.”
Deciphex’s innovative digital pathology solutions empower researchers and non-clinical pathologists to make more informed decisions through the use of cutting-edge technology. With the attainment of GLP certification, Deciphex is poised to offer its clients even greater confidence in the digital studies generated within its state-of-the-art Exeter facility.
As Deciphex enters this new phase of GLP-certified operations, the company remains dedicated to pushing the boundaries of digital pathology and contributing to the evolution of solutions that improve patient outcomes globally. Deciphex operates centers of excellence for GLP slide scanning in the US (Naperville, IL) and UK (Exeter).
FOR MEDIA INQUIRIES OR FURTHER INFORMATION, PLEASE CONTACT:
Charli-Ann Lynch
Digital Marketing Specialist
charli-ann.lynch@deciphex.com
+353 972401459
About Deciphex:
Deciphex is a leading provider of digital pathology solutions that empower healthcare professionals with advanced tools for accurate and efficient diagnosis. By combining cutting-edge technology with a commitment to quality and regulatory compliance, Deciphex is at the forefront of driving advancements in digital pathology. With GLP certification at its Exeter site, Deciphex further solidifies its position as a trusted partner for clients seeking precision, reliability, and innovation in their research and development endeavours.
SOURCE: Deciphex
